The N15DOP study, sponsored by The Netherlands Cancer Institute, aimed to evaluate the safety and tolerability of oral ModraDoc006/r in combination with hormonal therapy and high-dose intensity-modulated radiation therapy for high-risk early-stage prostate cancer. Despite the promising rationale based on recent trials indicating improved survival outcomes with early systemic treatment, the trial was terminated due to low patient enrollment and availability of the investigational product (IP). This raises concerns regarding the market viability of ModraDoc006/r, especially in a competitive landscape where intravenous docetaxel remains a standard treatment. The findings may impact future development strategies and partnerships for oral formulations of chemotherapeutics in oncology.